Syra Health Slashes FY2025 Net Loss by 76%, Targets 2026 Profitability on 157% Population Health Growth
SYRA has more than doubled off its 52-week low of $0.031.
Summary
Syra Health reported strong operational improvements for FY2025, significantly reducing its net loss by 76% to $896K and improving EPS from ($0.50) to ($0.08). The company achieved robust 157% growth in its higher-margin population health revenue, reaching $5.3 million, while also cutting operating expenses by 37% and boosting gross margins. Despite a 9% decline in overall revenue due to federal funding shifts, these results demonstrate a clear path towards the company's stated goal of achieving profitability by year-end 2026. For a micro-cap company, this substantial progress in cost management and segment growth is highly material, indicating a potential turnaround. Traders will closely watch the company's execution on its profitability target and continued expansion in its population health solutions.
At the time of this announcement, SYRA was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.03 to $0.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.